DK3679946T3 - Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin - Google Patents

Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin Download PDF

Info

Publication number: DK3679946T3
Authority: DK; Denmark
Prior art keywords: tryptophan; tyrosine; formulation stabilized; neurotoxin formulation; liquid
Prior art date: 2016-05-27

Application number

DK20152386.7T

Other languages

English (en)

Inventor

Anders Jarstad

Anna Friis

Ulf Stahl

Ann Gurell

Barbro Agren

Emilia Edstrom

Andrew Pickett

Original Assignee

Ipsen Biopharm Ltd

Galderma Holding SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-27

Filing date

2017-05-26

Publication date

2022-02-07

2017-05-26 Application filed by Ipsen Biopharm Ltd, Galderma Holding SA filed Critical Ipsen Biopharm Ltd

2022-02-07 Application granted granted Critical

2022-02-07 Publication of DK3679946T3 publication Critical patent/DK3679946T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Birds (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gerontology & Geriatric Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Medicinal Preparation (AREA)

DK20152386.7T 2016-05-27 2017-05-26 Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin DK3679946T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2016062085		2016-05-27
EP17728095.5A EP3463432B1 (en)	2016-05-27	2017-05-26	Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

Publications (1)

Publication Number	Publication Date
DK3679946T3 true DK3679946T3 (da)	2022-02-07

Family

ID=56289455

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK21211390.6T DK4026532T3 (da)	2016-05-27	2017-05-26	Flydende neurotoxinformulering stabiliseret med tryptophan eller tyrosin
DK17728095.5T DK3463432T3 (da)	2016-05-27	2017-05-26	Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin
DK20152386.7T DK3679946T3 (da)	2016-05-27	2017-05-26	Flydende neurotoksinformulering stabiliseret med tryptophan eller tyrosin

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK21211390.6T DK4026532T3 (da)	2016-05-27	2017-05-26	Flydende neurotoxinformulering stabiliseret med tryptophan eller tyrosin
DK17728095.5T DK3463432T3 (da)	2016-05-27	2017-05-26	Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin

Country Status (31)

Country	Link
US (5)	US20190183988A1 (da)
EP (3)	EP4026532B1 (da)
JP (1)	JP7053498B2 (da)
KR (2)	KR102423739B1 (da)
CN (2)	CN111701010B (da)
AR (1)	AR108631A1 (da)
AU (1)	AU2017270359B2 (da)
BR (1)	BR112018074311A2 (da)
CA (1)	CA3025437A1 (da)
CY (2)	CY1124237T1 (da)
DK (3)	DK4026532T3 (da)
EA (1)	EA038124B1 (da)
ES (2)	ES2846350T3 (da)
GE (1)	GEP20207139B (da)
HR (2)	HRP20202070T1 (da)
HU (2)	HUE057640T2 (da)
IL (2)	IL285190B (da)
LT (2)	LT3679946T (da)
MX (1)	MX392529B (da)
PL (2)	PL3463432T3 (da)
PT (2)	PT3463432T (da)
RS (2)	RS61340B1 (da)
RU (1)	RU2741497C9 (da)
SA (1)	SA518400513B1 (da)
SG (1)	SG11201810561YA (da)
SI (2)	SI3679946T1 (da)
SM (2)	SMT202100003T1 (da)
TW (1)	TWI777955B (da)
UA (1)	UA123679C2 (da)
WO (1)	WO2017203038A1 (da)
ZA (1)	ZA201807904B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8168206B1 (en)	2005-10-06	2012-05-01	Allergan, Inc.	Animal protein-free pharmaceutical compositions
HRP20180739T1 (hr)	2008-12-31	2018-06-29	Revance Therapeutics, Inc.	Injekcijske formulacije botulinskog toksina
CA2766521C (en)	2009-06-25	2020-07-21	Revance Therapeutics, Inc.	Albumin-free botulinum toxin formulations
US9480731B2 (en)	2013-12-12	2016-11-01	Medy-Tox, Inc.	Long lasting effect of new botulinum toxin formulations
HUE046449T2 (hu)	2016-09-13	2020-03-30	Allergan Inc	Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
US11149262B2 (en) *	2017-12-20	2021-10-19	Alleergan, Inc.	Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
UY38744A (es) *	2019-06-07	2020-12-31	Nestle Skin Health S A	Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
CN116440281A (zh) *	2022-01-07	2023-07-18	重庆誉颜制药有限公司	一种肉毒毒素蛋白组合物
JP2025500698A (ja) *	2022-01-14	2025-01-09	ガルデルマ・ホールディング・エスアー	中等度から最重度の眉間皺及び外眼角皺の治療
MX2024009970A (es)	2022-02-15	2024-09-18	Merz Pharma Gmbh & Co Kgaa	Formulacion liquida de toxina botulinica y uso de la misma.
WO2025032220A1 (en)	2023-08-10	2025-02-13	Merz Pharma Gmbh & Co. Kgaa	Liquid botulinum toxin formulation and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI240627B (en) *	1996-04-26	2005-10-01	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
CA2494241C (en)	2000-02-08	2011-06-14	Allergan, Inc.	Botulinum toxin pharmaceutical compositions
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) *	2000-02-08	2006-11-30	Allergan, Inc.	Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
JP4683810B2 (ja) *	2000-02-29	2011-05-18	中外製薬株式会社	長期安定化製剤
US6627602B2 (en) *	2001-11-13	2003-09-30	Duke University	Preventing desensitization of receptors
DE10333317A1 (de)	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en)	2004-07-12	2006-01-18	Ipsen Ltd	Botulinum neurotoxin composition
BRPI0513850A (pt) *	2004-07-26	2008-05-20	Merz Pharma Gmbh & Co Kgaa	composição terapêutica com uma neurotoxina botulìnica
US20080102090A1 (en) *	2004-08-04	2008-05-01	Naveed Panjwani	Pharmaceutical Compositon Containing Botulinum Neurotoxin A2
US20080220021A1 (en) *	2005-02-14	2008-09-11	Pankaj Modi	Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
FR2902341B1 (fr)	2006-06-16	2011-02-25	Scras	Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
CA2690773C (en)	2007-07-10	2013-09-17	Medy-Tox, Inc.	Pharmaceutical liquid composition of botulinum toxin with improved stability
US9107815B2 (en) *	2008-02-22	2015-08-18	Allergan, Inc.	Sustained release poloxamer containing pharmaceutical compositions
CA2774951C (en)	2009-09-24	2014-12-16	Allergan, Inc.	Method of treating osteoporosis with a neurotoxin
CN103842819B (zh)	2011-06-01	2017-09-12	拜奥麦迪逊公司	非‑fret肉毒梭菌测定法
LT2761065T (lt)	2011-09-29	2018-01-10	Cellsnap, Llc	Kompozicijos ir būdai toksigeniškumo testavimui
KR101357999B1 (ko) *	2012-03-20	2014-02-03	함종욱	보툴리눔 에이형 독소의 액상제품
EP3052120A1 (en)	2013-09-30	2016-08-10	Galderma S.A.	Prostate cancer treatment
GB201407525D0 (en) *	2014-04-29	2014-06-11	Syntaxin Ltd	Manufacture of recombinant clostridium botulinum neurotoxins

2017
- 2017-05-26 EP EP21211390.6A patent/EP4026532B1/en active Active
- 2017-05-26 KR KR1020227012437A patent/KR102423739B1/ko active Active
- 2017-05-26 PT PT177280955T patent/PT3463432T/pt unknown
- 2017-05-26 ES ES17728095T patent/ES2846350T3/es active Active
- 2017-05-26 RU RU2018142149A patent/RU2741497C9/ru active
- 2017-05-26 SI SI201731069T patent/SI3679946T1/sl unknown
- 2017-05-26 SI SI201730582T patent/SI3463432T1/sl unknown
- 2017-05-26 JP JP2018562171A patent/JP7053498B2/ja active Active
- 2017-05-26 HR HRP20202070TT patent/HRP20202070T1/hr unknown
- 2017-05-26 DK DK21211390.6T patent/DK4026532T3/da active
- 2017-05-26 EP EP17728095.5A patent/EP3463432B1/en active Active
- 2017-05-26 SM SM20210003T patent/SMT202100003T1/it unknown
- 2017-05-26 HU HUE20152386A patent/HUE057640T2/hu unknown
- 2017-05-26 RS RS20201596A patent/RS61340B1/sr unknown
- 2017-05-26 RS RS20220045A patent/RS62832B1/sr unknown
- 2017-05-26 BR BR112018074311A patent/BR112018074311A2/pt unknown
- 2017-05-26 LT LTEP20152386.7T patent/LT3679946T/lt unknown
- 2017-05-26 SM SM20220080T patent/SMT202200080T1/it unknown
- 2017-05-26 CA CA3025437A patent/CA3025437A1/en active Pending
- 2017-05-26 GE GEAP201714939A patent/GEP20207139B/en unknown
- 2017-05-26 TW TW106117499A patent/TWI777955B/zh active
- 2017-05-26 DK DK17728095.5T patent/DK3463432T3/da active
- 2017-05-26 EA EA201892493A patent/EA038124B1/ru unknown
- 2017-05-26 DK DK20152386.7T patent/DK3679946T3/da active
- 2017-05-26 IL IL285190A patent/IL285190B/en unknown
- 2017-05-26 HR HRP20220024TT patent/HRP20220024T1/hr unknown
- 2017-05-26 US US16/304,986 patent/US20190183988A1/en not_active Abandoned
- 2017-05-26 MX MX2018014631A patent/MX392529B/es unknown
- 2017-05-26 HU HUE17728095A patent/HUE052023T2/hu unknown
- 2017-05-26 CN CN202010742639.2A patent/CN111701010B/zh active Active
- 2017-05-26 ES ES20152386T patent/ES2911124T3/es active Active
- 2017-05-26 PT PT201523867T patent/PT3679946T/pt unknown
- 2017-05-26 WO PCT/EP2017/062785 patent/WO2017203038A1/en not_active Ceased
- 2017-05-26 LT LTEP17728095.5T patent/LT3463432T/lt unknown
- 2017-05-26 AU AU2017270359A patent/AU2017270359B2/en active Active
- 2017-05-26 SG SG11201810561YA patent/SG11201810561YA/en unknown
- 2017-05-26 KR KR1020187037095A patent/KR102399451B1/ko active Active
- 2017-05-26 UA UAA201811606A patent/UA123679C2/uk unknown
- 2017-05-26 CN CN201780044565.1A patent/CN109562148A/zh active Pending
- 2017-05-26 EP EP20152386.7A patent/EP3679946B1/en active Active
- 2017-05-26 PL PL17728095T patent/PL3463432T3/pl unknown
- 2017-05-26 PL PL20152386T patent/PL3679946T3/pl unknown
- 2017-05-29 AR ARP170101464A patent/AR108631A1/es active IP Right Grant
2018
- 2018-11-21 IL IL263173A patent/IL263173B/en unknown
- 2018-11-22 ZA ZA2018/07904A patent/ZA201807904B/en unknown
- 2018-11-26 SA SA518400513A patent/SA518400513B1/ar unknown
2021
- 2021-01-05 CY CY20211100001T patent/CY1124237T1/el unknown
- 2021-06-28 US US17/304,888 patent/US20230190892A9/en not_active Abandoned
2022
- 2022-01-25 CY CY20221100057T patent/CY1124916T1/el unknown
2023
- 2023-02-24 US US18/173,991 patent/US20230181702A1/en not_active Abandoned
- 2023-09-28 US US18/476,731 patent/US12285468B2/en active Active
2025
- 2025-04-25 US US19/189,864 patent/US20250255943A1/en active Pending

Also Published As

Publication number	Publication date
HRP20220024T1 (hr)	2022-04-01
IL263173A (en)	2018-12-31
UA123679C2 (uk)	2021-05-12
JP7053498B2 (ja)	2022-04-12
RU2018142149A3 (da)	2020-07-23
DK3463432T3 (da)	2021-01-04
CY1124916T1 (el)	2023-01-05
US20190183988A1 (en)	2019-06-20
US20230190892A9 (en)	2023-06-22
KR20190022548A (ko)	2019-03-06
SI3463432T1 (sl)	2021-02-26
EP3679946A1 (en)	2020-07-15
NZ748626A (en)	2025-05-02
RS61340B1 (sr)	2021-02-26
PT3463432T (pt)	2021-01-12
SG11201810561YA (en)	2018-12-28
CN111701010B (zh)	2023-09-26
RU2741497C2 (ru)	2021-01-26
US20240050539A1 (en)	2024-02-15
IL285190A (en)	2021-08-31
MX392529B (es)	2025-03-21
KR20220054887A (ko)	2022-05-03
ES2846350T3 (es)	2021-07-28
HUE057640T2 (hu)	2022-05-28
AR108631A1 (es)	2018-09-12
LT3463432T (lt)	2021-01-25
PL3679946T3 (pl)	2022-05-30
SA518400513B1 (ar)	2022-11-03
LT3679946T (lt)	2022-02-10
WO2017203038A1 (en)	2017-11-30
US20250255943A1 (en)	2025-08-14
SI3679946T1 (sl)	2022-04-29
KR102399451B1 (ko)	2022-05-23
HRP20202070T1 (hr)	2021-02-19
HUE052023T2 (hu)	2021-04-28
KR102423739B1 (ko)	2022-07-21
PL3463432T3 (pl)	2021-04-19
US20210330765A1 (en)	2021-10-28
AU2017270359B2 (en)	2023-09-21
DK4026532T3 (da)	2025-12-08
EP4026532B1 (en)	2025-11-26
BR112018074311A2 (pt)	2019-10-01
TWI777955B (zh)	2022-09-21
MX2018014631A (es)	2019-06-12
CY1124237T1 (el)	2022-07-22
RS62832B1 (sr)	2022-02-28
IL285190B (en)	2022-07-01
SMT202200080T1 (it)	2022-03-21
JP2019517481A (ja)	2019-06-24
EP3463432A1 (en)	2019-04-10
EA201892493A1 (ru)	2019-04-30
EP3679946B1 (en)	2022-01-05
TW201742632A (zh)	2017-12-16
PT3679946T (pt)	2022-01-14
EP3463432B1 (en)	2020-10-07
CA3025437A1 (en)	2017-11-30
US12285468B2 (en)	2025-04-29
CN109562148A (zh)	2019-04-02
SMT202100003T1 (it)	2021-03-15
AU2017270359A1 (en)	2018-12-13
GEP20207139B (en)	2020-07-27
CN111701010A (zh)	2020-09-25
US20230181702A1 (en)	2023-06-15
ES2911124T3 (es)	2022-05-17
EP4026532A1 (en)	2022-07-13
EA038124B1 (ru)	2021-07-09
RU2741497C9 (ru)	2021-04-30
RU2018142149A (ru)	2020-06-29
ZA201807904B (en)	2020-05-27
IL263173B (en)	2021-08-31

Publication	Publication Date	Title
DK3463432T3 (da)	2021-01-04	Flydende neurotoksin-formulering stabiliseret med tryptofan eller tyrosin
HUE053889T2 (hu)	2021-07-28	Folyadék áramlását korlátozó eszköz
DK3127300T3 (da)	2019-10-07	Håndtering af nic-krypterede flows til at migrere gæster eller opgaver
DK3212208T3 (da)	2021-05-17	Anvendelse af l. reuteri til forebyggelse eller behandling af mikrobiotadysbiose tidligt i livet
DK3370828T3 (da)	2020-07-13	Oximforbindelse som agonister af muscarin m1- og/eller m4- receptoren
DK3197472T3 (da)	2021-10-18	Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3014279T3 (da)	2023-01-09	Fremgangsmåde til bestemmelse af proteinaggregater under anvendelse af overflade-fida
IL259721B (en)	2021-12-01	Methods for gender determination of avian embryos in unhatched eggs and means thereof
EP3558000C0 (en)	2025-08-20	COMPOSITIONS CONTAINING ACETIC ACID AND HYPOCHLOROUS ACID
EP3390626A4 (en)	2019-08-14	LIQUID FORMULATION OF ALPHA AMYLASE
PT3334747T (pt)	2023-12-12	Formulação de gonadotrofina líquida estável
DK3217963T3 (da)	2020-07-20	Fremgangsmåder til behandling af individer med prader-willis syndrom eller smith-magenis syndrom
EP3530264A4 (en)	2020-07-01	OIL-IN-WATER-TYPE EMULSION COMPOSITION
LT3419595T (lt)	2021-03-10	Stabili skysta gonadotropino kompozicija
IL264579A (en)	2019-02-28	Vial assembly with luer fitting
DK3535050T3 (da)	2022-06-27	Væskeblandingssystem med vertikalt justerbart blandeelement samt anvendelsesfremgangsmåde
EP3414517A4 (en)	2020-02-19	HOLOGRAPHIC CHARACTERIZATION OF PROTEIN AGGREGATES
DK3554501T3 (da)	2021-07-19	Dexmedetomidin eller medetomidin til anvendelse i behandling af separationsangst hos kæledyr
DK3330267T3 (da)	2022-03-14	Salt af quinazolinderivat eller crystal deraf samt fremgangsmåde til fremstilling af salt af quinazolinderivat eller crystal deraf
DK3742164T3 (da)	2022-02-21	Indretning til bestemmelse af tilstedeværelsen og/eller mængden af målmolekyler
HUE055016T2 (hu)	2021-10-28	Olaj-a-vízben nanoemulziós klobetazol készítmény
DK3380487T3 (da)	2020-12-07	Additivsystemer til anvendelse i proteinpegylering
EP3554483C0 (en)	2024-01-31	REDUCTION OF SIDE EFFECTS OF SHORT-ACTING NO DONORS
EP3305296A4 (en)	2019-02-13	AQUEOUS LIQUID FORMULATION
FI20155198L (fi)	2016-09-24	Aurinkokäyttöinen fluidipumppu ja siihen liittyvä järjestely